Publication: European Pharmaceutical Review

First reported 10 hours ago - Updated 10 hours ago - 1 reports

Probiodrug raises €22.5 million in successful Initial Public Offering and listing on Euronext Amsterdam

Probiodrug AG (“Probiodrug”), a biopharmaceutical company dedicated to the research and development of novel therapeutic solutions to treat people with Alzheimer’s Disease, announces the successful completion of its Initial Public Offering, which was ... [Published European Pharmaceutical Review - 10 hours ago]
First reported 10 hours ago - Updated 10 hours ago - 1 reports

Results announcement for the third quarter 2014

GSK announces Q3 core EPS of 27.9p +5% CER excluding divestments and dividend of 19 pence per share ... [Published European Pharmaceutical Review - 10 hours ago]
Entities: 9p, Dividend
First reported Oct 22 2014 - Updated Oct 23 2014 - 1 reports

Harvoni will keep Gilead atop Hepatitis C virus treatment landscape, says GlobalData Analyst

The recent US Food and Drug Administration (FDA) approval of Harvoni (ledipasvir/sofosbuvir), Gilead Sciences’ once-daily, single-tablet regimen to treat chronic hepatitis C virus (HCV) genotype 1 (GT1) infection in adults, will enable the company to ... [Published European Pharmaceutical Review - Oct 22 2014]
First reported Oct 22 2014 - Updated Oct 22 2014 - 1 reports

Tanzania to host The Economist Events’ Health Care in Africa 2014

Author(s): APO (African Press Organization) on behalf of The Economist Events The Economist Events (http://www.economistevents.com) will be hosting their Health Care in Africa Summit (http://www.africahealth.economist.com) in Dar es Salaam, Tanzania at ... [Published European Pharmaceutical Review - Oct 22 2014]
First reported Oct 21 2014 - Updated Oct 21 2014 - 1 reports

Calixar and Aston University together in collaborative research to tackle multidrug resistance targets

Aston University (Birmingham – UK) and Calixar SAS (Lyon-France) have concluded a new research agreement through the “BBSRC Industrial CASE Studentship Competition 2013” framework. The annual CASE competition for collaborative training awards provides ... [Published European Pharmaceutical Review - Oct 21 2014]
First reported Oct 20 2014 - Updated Oct 20 2014 - 1 reports

European Commission approves IMBRUVICATM in two forms of blood cancer

(Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor. This new approach to treating blood cancers works by blocking BTK, a protein ... [Published European Pharmaceutical Review - Oct 20 2014]
First reported Oct 20 2014 - Updated Oct 20 2014 - 1 reports

Demos: Migrant health access fears put vulnerable people at risk

A new report by the think-tank Demos, supported by Doctors of the World, argues that encouraging earlier detection of health conditions amongst migrant communities would reduce NHS spending on treatment and reduce the wider public health risk by catching ... [Published European Pharmaceutical Review - Oct 20 2014]
First reported Oct 20 2014 - Updated Oct 20 2014 - 1 reports

Nasdaq welcomes Forward Pharma A/S (Nasdaq: FWP) to The Nasdaq Stock Market

Nasdaq (Nasdaq: NDAQ) announced that trading of Forward Pharma A/S (Nasdaq: FWP) commenced on The Nasdaq Stock Market on October 15, 2014.Headquartered in Copenhagen, Denmark, Forward Pharma is a biopharmaceutical company focused on a proprietary formulation ... [Published European Pharmaceutical Review - Oct 20 2014]
First reported Oct 20 2014 - Updated Oct 20 2014 - 1 reports

Masters Speciality Pharma – celebrating 30 years in business

today celebrates the anniversary of its foundation by Dr Zulf Masters, OBE, 30 years ago. The company, which started with only humble beginnings in a third bedroom in a terraced house in South Harrow, has gone on to become a multi-million pound business ... [Published European Pharmaceutical Review - Oct 20 2014]
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

Foreword: ICH Q6A – Specifications: Test procedures and acceptance criteria for new drug substances and new drug products: chemical substances

Specifications (test and acceptance criteria) for active pharmaceutical ingredients (APIs) and drug products are defined in ICH Q6A. It ‘establishes a set of criteria to which a drug substance or drug product should conform to be considered acceptable ... [Published European Pharmaceutical Review - Oct 17 2014]
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

GEA interviewed at at CPhi 2014

Andrew Johnson speaks with Søren Terp Madsen, Area Sales Manager and Product Manager, Chemical Division – Pharma Spray Drying, GEA Niro at CPhi 2 ... [Published European Pharmaceutical Review - Oct 17 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

METTLER TOLEDO launch new XPE Balance portfolio designed for performance and ease of compliance

METTLER TOLEDO’s new line of XPE balances includes micro-analytical, analytical, and precision balances as well as automated dosing with the Quantos powder and liquid dispensing modules. Users can carry out their daily weighing tasks worry free, safe ... [Published European Pharmaceutical Review - Oct 16 2014]

More Content

All (67) | News (67) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Results announcement for the third quarter 2014 [Published European Pharmaceutical Review - 10 hours ago]
Probiodrug raises €22.5 million in successful I... [Published European Pharmaceutical Review - 10 hours ago]
Harvoni will keep Gilead atop Hepatitis C virus... [Published European Pharmaceutical Review - Oct 22 2014]
Tanzania to host The Economist Events’ Health C... [Published European Pharmaceutical Review - Oct 22 2014]
Calixar and Aston University together in collab... [Published European Pharmaceutical Review - Oct 21 2014]
European Commission approves IMBRUVICATM in two... [Published European Pharmaceutical Review - Oct 20 2014]
Nasdaq welcomes Forward Pharma A/S (Nasdaq: FWP... [Published European Pharmaceutical Review - Oct 20 2014]
Demos: Migrant health access fears put vulnerab... [Published European Pharmaceutical Review - Oct 20 2014]
Masters Speciality Pharma – celebrating 30 year... [Published European Pharmaceutical Review - Oct 20 2014]
Foreword: ICH Q6A – Specifications: Test proced... [Published European Pharmaceutical Review - Oct 17 2014]
GEA interviewed at at CPhi 2014 [Published European Pharmaceutical Review - Oct 17 2014]
METTLER TOLEDO launch new XPE Balance portfolio... [Published European Pharmaceutical Review - Oct 16 2014]
Public-private partnerships vital to advance Eb... [Published European Pharmaceutical Review - Oct 16 2014]
Promethera Biosciences receives approval in Bel... [Published European Pharmaceutical Review - Oct 15 2014]
Coulter Partners further strengthens its activi... [Published European Pharmaceutical Review - Oct 15 2014]
Auspherix and Domainex announce collaboration t... [Published European Pharmaceutical Review - Oct 15 2014]
Imaxio signs an option for a license agreement ... [Published European Pharmaceutical Review - Oct 14 2014]
New Oncology and Gustave Roussy announce collab... [Published European Pharmaceutical Review - Oct 14 2014]
Probiodrug launches its Initial Public Offering... [Published European Pharmaceutical Review - Oct 13 2014]
Evotec receives milestone as part of its multi-... [Published European Pharmaceutical Review - Oct 13 2014]
Janssen demonstrates continued commitment to co... [Published European Pharmaceutical Review - Oct 10 2014]
Bone Therapeutics extends ALLOB® phase I/IIa tr... [Published European Pharmaceutical Review - Oct 09 2014]
DOW-COLORCON Alliance will commercialize next-g... [Published European Pharmaceutical Review - Oct 09 2014]
Record attendance for CHI’s Sixth Annual PEGS E... [Published European Pharmaceutical Review - Oct 09 2014]
Avacta extends Optim® 2 product family for even... [Published European Pharmaceutical Review - Oct 09 2014]
New study shows UK public are largely unaware o... [Published European Pharmaceutical Review - Oct 09 2014]
Recent developments keep Gilead ahead of the pa... [Published European Pharmaceutical Review - Oct 08 2014]
CleveXel Pharma to license two new oncology pat... [Published European Pharmaceutical Review - Oct 06 2014]
Fast diagnosis: New mobile lab helps MOH fight ... [Published European Pharmaceutical Review - Oct 06 2014]
OBN celebrates the stars of UK Life Sciences [Published European Pharmaceutical Review - Oct 03 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.